Bavarian Nordic

Ask Sterling

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving the EV sector growth?

Favorites

Revenue Breakdown

Revenue Flow

Balance Sheet

Q2 2016-Q1 2026

Cash Flow

Q2 2016-Q1 2026

Bavarian Nordic

Specialty vaccines: Jynneos/Imvanex (mpox, smallpox) and Vimkunya (chikungunya, approved US/EU/UK in 2025). March 2026 Serum Institute tech-transfer for LMIC chikungunya supply.

$BAVA.COHellerup, Denmark1,400bavarian-nordic.com

SectorsVaccines

Frequently asked questions

What does Bavarian Nordic do?

Bavarian Nordic (BAVA.CO) is a Biotechnology company. Specialty vaccines: Jynneos/Imvanex (mpox, smallpox) and Vimkunya (chikungunya, approved US/EU/UK in 2025). March 2026 Serum Institute tech-transfer for LMIC chikungunya supply. It was founded in 1994, is headquartered in Hellerup, Denmark and employs about 1,400 people.

How has Bavarian Nordic's revenue and profitability trended?

Track Bavarian Nordic's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.

Who are Bavarian Nordic's main competitors?

Sterling groups Bavarian Nordic in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).

If I'm investing in Bavarian Nordic, what similar companies should I consider?

If you are researching Bavarian Nordic, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.